The Responsiveness of Bee Venom Phospholipase A2 on Regulatory T Cells Correlates with the CD11c + CD206 + Population in Human Peripheral Blood Mononuclear Cells

• Published in: Toxins 2021-10, Vol.13 (10), p.717
• Main Authors: Jo, Heejin, Baek, Hyunjung, Park, Seon-Young, Goo, Bonhyuk, Jung, Woo-Sang, Bae, Hyunsu, Nam, Sang-Soo
• Format: Article
• Language: English
• Subjects: Adult; Aged; Alzheimer's disease; Anticancer properties; bee venom phospholipase A2 (bvPLA2); Bee Venoms - enzymology; Bee Venoms - pharmacology; Blood; CD11c antigen; CD206; Correlation; Dendritic cells; Female; Flow cytometry; human peripheral blood mononuclear cell (hPBMC); Humans; Immunoregulation; Inflammation; Leukocytes (mononuclear); Leukocytes, Mononuclear - drug effects; Lymphocytes; Lymphocytes T; Male; Mannose; mannose receptor; Mannose Receptor - metabolism; Middle Aged; Monocytes; Neuroprotection; Pain perception; Parkinson's disease; Peripheral blood mononuclear cells; Phospholipase; Phospholipase A2; Phospholipases A2 - pharmacology; Population; Receptors, Cell Surface - metabolism; Regulation; regulatory T cell (Treg); Subpopulations; T-Lymphocytes, Regulatory - drug effects; Venom
• ISSN: 2072-6651; 2072-6651
• DOI: 10.3390/toxins13100717

Bee venom phospholipase A2 (bvPLA2) has been reported to have therapeutic effects such as neuroprotection, anti-inflammation, anti-nociception, anti-cancer properties, caused by increasing regulatory T cells (Tregs). The mechanism of Tregs modulation by bvPLA2 has been demonstrated by binding with the mannose receptor, CD206 in experimental models of several diseases. However, it remains unknown whether this mechanism can also be applied in human blood. In this study, we collected peripheral blood samples from healthy donors and analyzed the percentages of monocyte-derived dendritic cells with CD206 (CD206 DCs) before expansion, the proportion of Tregs, and the subpopulations after expansion treated with bvPLA2 or PBS using flow cytometry and the correlations among them. The percentage of Tregs tended to be higher in the bvPLA2 group than in the control group. There were significant positive correlations between the CD206 population in hPBMC and the proportions of Tregs treated with bvPLA2, especially in the Treg fold change comparing the increase ratio of Tregs in bvPLA2 and in PBS. These findings indicate that bvPLA2 increased the proportion of Tregs in healthy human peripheral blood and the number of CD206 DCs could be a predictor of the bvPLA2 response of different individuals.